CN102209729B - 小儿急性淋巴细胞白血病的治疗方法 - Google Patents

小儿急性淋巴细胞白血病的治疗方法 Download PDF

Info

Publication number
CN102209729B
CN102209729B CN200980144400.7A CN200980144400A CN102209729B CN 102209729 B CN102209729 B CN 102209729B CN 200980144400 A CN200980144400 A CN 200980144400A CN 102209729 B CN102209729 B CN 102209729B
Authority
CN
China
Prior art keywords
pediatric
patient
treatment
mrd
chain antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200980144400.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN102209729A (zh
Inventor
格哈德·祖格迈尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Research Munich GmbH
Original Assignee
Micromet GmbH
Amgen Research Munich GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micromet GmbH, Amgen Research Munich GmbH filed Critical Micromet GmbH
Priority to CN201610281293.4A priority Critical patent/CN106390114A/zh
Publication of CN102209729A publication Critical patent/CN102209729A/zh
Application granted granted Critical
Publication of CN102209729B publication Critical patent/CN102209729B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN200980144400.7A 2008-11-07 2009-11-06 小儿急性淋巴细胞白血病的治疗方法 Active CN102209729B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610281293.4A CN106390114A (zh) 2008-11-07 2009-11-06 小儿急性淋巴细胞白血病的治疗方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US11232308P 2008-11-07 2008-11-07
US61/112,323 2008-11-07
US18329109P 2009-06-02 2009-06-02
US61/183,291 2009-06-02
US22126909P 2009-06-29 2009-06-29
US61/221,269 2009-06-29
PCT/EP2009/007969 WO2010052013A1 (en) 2008-11-07 2009-11-06 Treatment of pediatric acute lymphoblastic leukemia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610281293.4A Division CN106390114A (zh) 2008-11-07 2009-11-06 小儿急性淋巴细胞白血病的治疗方法

Publications (2)

Publication Number Publication Date
CN102209729A CN102209729A (zh) 2011-10-05
CN102209729B true CN102209729B (zh) 2016-05-25

Family

ID=41796119

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200980144400.7A Active CN102209729B (zh) 2008-11-07 2009-11-06 小儿急性淋巴细胞白血病的治疗方法
CN201610281293.4A Pending CN106390114A (zh) 2008-11-07 2009-11-06 小儿急性淋巴细胞白血病的治疗方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610281293.4A Pending CN106390114A (zh) 2008-11-07 2009-11-06 小儿急性淋巴细胞白血病的治疗方法

Country Status (27)

Country Link
US (2) US20110262440A1 (https=)
EP (4) EP2344539B1 (https=)
JP (2) JP5798036B2 (https=)
KR (1) KR101695329B1 (https=)
CN (2) CN102209729B (https=)
AU (1) AU2009313039B2 (https=)
BR (1) BRPI0921341A2 (https=)
CA (1) CA2742242C (https=)
CY (3) CY1116160T1 (https=)
DK (3) DK2918604T3 (https=)
ES (3) ES2748126T3 (https=)
HK (1) HK1255590B (https=)
HR (3) HRP20150400T1 (https=)
HU (3) HUE046222T2 (https=)
IL (1) IL212651A (https=)
LT (2) LT3330293T (https=)
MX (1) MX2011002931A (https=)
NO (1) NO2918604T3 (https=)
NZ (1) NZ591312A (https=)
PL (3) PL2918604T3 (https=)
PT (3) PT3330293T (https=)
RS (3) RS59348B1 (https=)
RU (3) RU2536933C2 (https=)
SG (1) SG195549A1 (https=)
SI (3) SI2344539T1 (https=)
SM (3) SMT201900546T1 (https=)
WO (1) WO2010052013A1 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6358588A (ja) * 1986-08-29 1988-03-14 Toshiba Corp バ−コ−ド読取装置
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
PT3330293T (pt) * 2008-11-07 2019-10-18 Amgen Res Munich Gmbh Tratamento da leucemia linfoblástica aguda pediátrica com anticorpos biespecíficos contra cd3xcd19
EP2386062B1 (en) * 2009-01-09 2016-01-06 Oxford Biomedica (UK) Ltd Factors
US20150231241A1 (en) * 2012-08-14 2015-08-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
WO2014075788A1 (en) * 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
CN103131777A (zh) * 2013-02-05 2013-06-05 南京艾迪康医学检验所有限公司 用于检测e2a-pbx融合基因相对表达量的试剂盒
DK3105252T3 (da) 2014-02-12 2019-10-14 Michael Uhlin Bispecifikke antistoffer til anvendelse ved stamcelletransplantation
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
ES2715679T3 (es) 2014-05-30 2019-06-05 Amgen Res Munich Gmbh Estratificación del riesgo de pacientes con leucemia linfoblástica aguda de precursores B
US20170252364A1 (en) * 2014-07-30 2017-09-07 Mor Research Applications Ltd. Compositions for treatment of acute lymphoblastic leukemia and methods of use thereof
WO2016061368A1 (en) * 2014-10-15 2016-04-21 The Children's Hospital Of Philadelphia Compositions and methods for treating b-lymphoid malignancies
RS60739B1 (sr) 2014-11-17 2020-09-30 Regeneron Pharma Postupci za lečenje tumora upotrebom cd3xcd20 bispecifičnog antitela
HK1250146A1 (zh) 2015-02-05 2018-11-30 Stc.Unm 抗前-bcr拮抗剂和方法
CA2981312C (en) 2015-03-30 2023-09-26 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
MX2017012939A (es) 2015-04-08 2018-05-22 Novartis Ag Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
RS66511B1 (sr) 2015-05-20 2025-03-31 Amgen Res Munich Gmbh Deplecija b ćelija kao dijagnostički marker
LT3353212T (lt) 2015-09-23 2021-12-27 Regeneron Pharmaceuticals, Inc. Optimizuoti anti-cd3 bispecifiniai antikūnai ir jų naudojimas
AU2016378573A1 (en) * 2015-12-22 2018-07-19 Regeneron Pharmaceuticals, Inc. Bispecific anti-CD20/anti-CD3 antibodies to treat acute lymphoblastic leukemia
GB201602974D0 (en) * 2016-02-19 2016-04-06 Clube Jasper R Engineered cells & methods (1)
IL261750B2 (en) * 2016-03-14 2024-07-01 Millennium Pharm Inc Method of preventing graft versus host disease
MA45341A (fr) * 2016-06-06 2019-04-10 Hutchinson Fred Cancer Res Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive
MA46995A (fr) 2016-12-03 2019-10-09 Acerta Pharma Bv Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase
MX2019013142A (es) * 2017-05-05 2019-12-16 Amgen Inc Composicion farmaceutica que comprende construcciones de anticuerpos biespecificas para mejorar el almacenamiento y la administracion.
AU2018275894B2 (en) 2017-06-02 2025-04-24 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
KR102083481B1 (ko) 2018-03-22 2020-03-02 강원대학교산학협력단 아연-키토산 나노 입자를 포함한 급성 림프구성 백혈병 치료용 약학조성물
RS66543B1 (sr) 2018-08-31 2025-03-31 Regeneron Pharma Strategija doziranja koja ublažava sindrom oslobađanja citokina za cd3/cd20 bispecifična antitela
WO2020160310A1 (en) * 2019-01-30 2020-08-06 The Wistar Institute Of Anatomy And Biology Dna-encoded bispecific t-cell engagers targeting cancer antigens and methods of use in cancer theraputics
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
PE20220568A1 (es) 2019-05-21 2022-04-20 Novartis Ag Moleculas de union a cd19 y usos de las mismas
WO2021006199A1 (ja) 2019-07-05 2021-01-14 小野薬品工業株式会社 Ｐｄ－１／ｃｄ３二重特異性タンパク質による血液がん治療
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
US12285494B2 (en) 2021-02-16 2025-04-29 Children's Health Care Methods for treating B-ALL by administering a pre-BCR complex antagonist
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
US20250282864A1 (en) 2021-10-15 2025-09-11 Amgen Research (Munich) Gmbh Subcutaneous administration of cd19-binding t cell engagers
US20250146017A1 (en) 2023-11-06 2025-05-08 City Of Hope Methods comprising oncolytic viruses expressing cd19t and bispecific t cell engagers
TW202535949A (zh) 2023-12-20 2025-09-16 美商必治妥美雅史谷比公司 靶向IL-18受體β(IL-18RB)之抗體及相關方法
WO2025250648A1 (en) * 2024-05-28 2025-12-04 Ohio State Innovation Foundation Methods and compositions comprising tagless blinatumomab
WO2026072671A1 (en) 2024-09-24 2026-04-02 City Of Hope Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1299410A (zh) * 1998-04-21 2001-06-13 麦克美特(显微医学)生物医学研究有限公司 CD19xCD3特异性多肽及其用途
CN1795208A (zh) * 2003-05-31 2006-06-28 麦克罗梅特股份公司 用于治疗b细胞相关疾病的包含双特异性抗cd3、抗cd19抗体构建体的药物组合物
WO2007068354A1 (en) * 2005-12-16 2007-06-21 Micromet Ag Means and methods for the treatment of tumorous diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4119397A (en) * 1996-08-28 1998-03-19 Viva Diagnostika Diagnostische Produkte Gmbh Novel combination preparations and their use in immunodiagnosis and immunotherapy
DE602004030811D1 (de) * 2003-10-16 2011-02-10 Micromet Ag Multispezifische deimmunisierte cd3-bindende moleküle
PL2383297T3 (pl) * 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
PL2352763T5 (pl) * 2008-10-01 2023-01-30 Amgen Research (Munich) Gmbh Bispecyficzne przeciwciała jednołańcuchowe o specyficzności wobec antygenów docelowych o dużej masie cząsteczkowej
PT3330293T (pt) * 2008-11-07 2019-10-18 Amgen Res Munich Gmbh Tratamento da leucemia linfoblástica aguda pediátrica com anticorpos biespecíficos contra cd3xcd19
CN102282128B (zh) * 2009-01-19 2015-06-17 Abbvie公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
CN102282129A (zh) * 2009-01-19 2011-12-14 雅培制药有限公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
MX2011012632A (es) * 2009-05-27 2012-03-06 Abbott Lab Inhibidores de actividad de cinasa tipo pirimidina.
BR112012006252A2 (pt) * 2009-09-20 2017-05-23 Abbott Lab "formas cristalinas de abt-263 e solvatos para o uso no tratamento de doenças relacionadas á proteína bcl-2".
CN107227335A (zh) * 2009-10-27 2017-10-03 安进研发（慕尼黑）股份有限公司 用于施用CD19xCD3双特异性抗体的给药方案

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1299410A (zh) * 1998-04-21 2001-06-13 麦克美特(显微医学)生物医学研究有限公司 CD19xCD3特异性多肽及其用途
CN1795208A (zh) * 2003-05-31 2006-06-28 麦克罗梅特股份公司 用于治疗b细胞相关疾病的包含双特异性抗cd3、抗cd19抗体构建体的药物组合物
WO2007068354A1 (en) * 2005-12-16 2007-06-21 Micromet Ag Means and methods for the treatment of tumorous diseases

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
11) acute lymphoblastic leukemia cells by activated CD3 antigen positive cytotoxic T cells.《Blood》.1992,第80卷(第11期),摘要及第2827页第3段. *
A recombinant bispecific single-chain antibody, CD19 × CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes;Anja Loffler et al;《Blood》;20001231;第95卷;2098-2103页 *
Acute lymphoblastic leukaemia;Ching-Hon Pui et al;《lancet》;20080322;第371卷(第9617期);1030-1043页 *
phase II study of the BiTE blinatumomab in patients with minimal residual disease of B-precursor acute all;Anomynous;《ClinicalTials.gov archive》;20080811;全文 *
PM Anderson et al.G19.4(alpha CD3) x B43(alpha CD19) monoclonal antibody heteroconjugate triggers CD19 antigen-specific lysis of t(4 *
Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody;Ralf Bargou et al;《Science》;20080815;第321卷(第5891期);摘要、第974页左栏第1行至第976页右栏第27行 *

Also Published As

Publication number Publication date
DK2918604T3 (en) 2018-03-19
SI2344539T1 (sl) 2015-06-30
EP2918604B1 (en) 2017-12-20
JP2015232023A (ja) 2015-12-24
JP2012508163A (ja) 2012-04-05
ES2662929T3 (es) 2018-04-10
NZ591312A (en) 2012-09-28
CY1116160T1 (el) 2017-02-08
RU2018144313A3 (https=) 2020-06-15
CY1122428T1 (el) 2021-01-27
KR20110091669A (ko) 2011-08-12
ES2748126T3 (es) 2020-03-13
HRP20180426T1 (hr) 2018-04-20
RS56989B1 (sr) 2018-05-31
RU2536933C2 (ru) 2014-12-27
HRP20191715T1 (hr) 2019-12-13
CA2742242A1 (en) 2010-05-14
IL212651A0 (en) 2011-07-31
MX2011002931A (es) 2011-04-11
IL212651A (en) 2015-03-31
LT3330293T (lt) 2019-10-10
JP6130451B2 (ja) 2017-05-17
RU2677324C2 (ru) 2019-01-16
HK1215258A1 (en) 2016-08-19
CY1120022T1 (el) 2018-12-12
SMT201900546T1 (it) 2019-11-13
PT2344539E (pt) 2015-04-01
PL3330293T3 (pl) 2020-02-28
CA2742242C (en) 2023-01-10
HUE046222T2 (hu) 2020-02-28
RU2018144313A (ru) 2020-06-15
DK2344539T3 (en) 2015-05-04
EP3594237A1 (en) 2020-01-15
HK1255590B (en) 2020-07-10
BRPI0921341A2 (pt) 2016-04-26
PT3330293T (pt) 2019-10-18
LT2918604T (lt) 2018-03-26
SMT201800149T1 (it) 2018-05-02
HUE025452T2 (en) 2016-05-30
RS53980B1 (sr) 2015-10-30
AU2009313039A1 (en) 2010-05-14
NO2918604T3 (https=) 2018-05-19
US20230235053A1 (en) 2023-07-27
EP3330293B1 (en) 2019-07-24
PL2344539T3 (pl) 2015-07-31
SI2918604T1 (en) 2018-04-30
SI3330293T1 (sl) 2019-10-30
AU2009313039B2 (en) 2015-06-18
RU2736802C2 (ru) 2020-11-20
HRP20150400T1 (hr) 2015-05-08
HUE036922T2 (hu) 2018-08-28
CN102209729A (zh) 2011-10-05
PT2918604T (pt) 2018-03-02
US20110262440A1 (en) 2011-10-27
PL2918604T3 (pl) 2018-05-30
EP2918604A1 (en) 2015-09-16
JP5798036B2 (ja) 2015-10-21
RS59348B1 (sr) 2019-10-31
SMT201500104B (it) 2015-07-09
ES2535257T3 (es) 2015-05-07
RU2014141180A3 (https=) 2018-06-09
EP3330293A1 (en) 2018-06-06
EP2344539A1 (en) 2011-07-20
HK1158667A1 (en) 2012-07-20
KR101695329B1 (ko) 2017-01-23
WO2010052013A1 (en) 2010-05-14
DK3330293T3 (da) 2019-10-07
RU2014141180A (ru) 2016-05-10
CN106390114A (zh) 2017-02-15
SG195549A1 (en) 2013-12-30
EP2344539B1 (en) 2015-02-11
RU2011122827A (ru) 2012-12-20

Similar Documents

Publication Publication Date Title
CN102209729B (zh) 小儿急性淋巴细胞白血病的治疗方法
HK1255590A1 (en) Treatment of pediatric acute lymphoblastic leukemia with bispecific antibodies against cd3xcd19
JP5955921B2 (ja) 急性リンパ芽球性白血病の治療
HK40022438A (en) Treatment of pediatric acute lymphoblastic leukemia
HK1215258B (en) Treatment of pediatric acute lymphoblastic leukemia
HK1158667B (en) Treatment of pediatric acute lymphoblastic leukemia

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Munich, Germany

Applicant after: AMGEN RESEARCH (MUNICH) GmbH

Address before: Munich, Germany

Applicant before: Matt mikeluo Limited by Share Ltd.

Address after: Munich, Germany

Applicant after: Matt mikeluo Limited by Share Ltd.

Address before: Munich, Germany

Applicant before: Micromet AG

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: MICROMET AG TO: AMGEN RESEARCH MUNICH GMBH

C14 Grant of patent or utility model
GR01 Patent grant